According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...

New studies in JACC highlight improvements in cardiac structure and function among CABG patients, as well as changes in ...

Similarly, zinc may contribute to GI issues like diarrhea or cramping. Many immune-supporting supplements combine vitamin C ...

Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announced that dosing has been completed for human pilot study #3 investigating a DehydraTECH-processed version of the dual ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...